---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-034464"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2026-02-03T23:59:59+00:00"
generated_at: "2026-05-16T05:25:29.980674+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kyverna appoints Mayo Pujols as CTO; Karen Walker retires effective Feb 9, 2026

## Summary
- Mayo Pujols named CTO effective Feb 9, bringing 30+ years in CAR T and cell therapy manufacturing.
- Outgoing CTO Karen Walker retires; will consult on BLA submission for miv-cel in stiff person syndrome.
- Pujols receives an inducement option for 300,000 shares vesting over 4 years under the 2024 Inducement Plan.
- The inducement plan was amended to increase authorized shares by 1,000,000 to 5,000,000 total.
- Kyverna advances toward potential commercial launch of miv-cel for autoimmune diseases.

## SEC filing metadata
- accession: 0001193125-26-034464
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2026-02-03T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000119312526034464/0001193125-26-034464-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000119312526034464/kytx-20260129.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-034464
- JSON: https://secwatch.observer/filing/0001193125-26-034464.json
- Plain text: https://secwatch.observer/filing/0001193125-26-034464.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.